Immunai

Biotech & Life Sciences · New York City, United States · Founded 2019

Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes

Valuation $1–2.5B

Headcount 100–500

Unlock exact values

Power Law Unicorn$1–10B valuation tier

Talent graph

Immunai's talent

Book a demo to see the people

Employees mapped 176 incl. 20 AI specialists

Founders /100 quality score

Key operators 16 quality /100

Potential founders likely future founders

Startup mafia 4 alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on Immunai's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

Viola Ventures

TLV Partners

Series A 4 investors entered at this stage

Dexcel Pharma

Schusterman Foundation

Catalio Capital Management

Duquesne Family Office

Series B+ 9 investors entered at this stage

Stanford University

Koch Disruptive Technologies

Icon Ventures

Parker Institute for Cancer Immunotherapy

Alexandria Venture Investments

Talos

8VC

Piedmont Healthcare

Massachusetts Institute of Technology

Immunai mafia

Startups founded by Immunai alumni

Former Immunai employees who went on to start their own companies. Sorted by Dealroom signal score.

PhaseVEst. 2023

Raviv PrylukIsrael

Signal score93

Jimini HealthEst. 2023

Luis VolochUnited States

Signal score88

DermagnostixEst. 2021

Fabian TheisGermany

Signal score81

Santa Ana BioEst. 2021

Danny WellsUnited States

Signal score66

Book a demo to explore the full alumni network →

Global footprint

Where Immunai has talent and traffic

Workforce by country

8 countries with
team presence

🇮🇱 Israel42%

🇺🇸 United States39.4%

🇨🇿 Czech Republic12%

🇨🇭 Switzerland3.9%

🇩🇪 Germany1.1%

Top 5 of 8 shown

Web traffic by country

6.4K monthly visits
across markets

🇺🇸 United States67.2%

🇮🇳 India18.8%

🇮🇱 Israel12.5%

🇩🇪 Germany1.6%

Top 4 markets shown

Patent intelligence

$90k patent portfolio · 3 active families

Estimated portfolio value

$90k

<0.01% of valuation · 90.8× smaller than top peer Sophia Genetics ($8M)

3 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Immunai

An AI-synthesized read of the highest-engagement posts about Immunai on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immunai on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles